Filing Details
- Accession Number:
- 0001127602-25-006284
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-21 20:07:07
- Reporting Period:
- 2025-02-19
- Filing Date:
- 2025-02-21
- Accepted Time:
- 2025-02-21 20:07:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1677950 | Esteban Santos | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Evp, Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-02-19 | 8,711 | $156.35 | 80,257 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-02-19 | 8,711 | $292.84 | 71,546 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Nqso (Right to Buy) | Disposition | 2025-02-19 | 8,711 | $0.00 | 8,711 | $156.35 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2018-05-03 | 2026-05-03 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 869 | Indirect | 401K Plan |
Footnotes
- These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
- The price reported is an average price. The prices ranged from $292.7523 to $293.00 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.